Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]
Discontinued
Reference number: GID-TA11277
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin late October 2024. The deadline for submissions is expected in approximately early January 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to align with regulatory timelines.
Although timelines have changed this does not affect the scoping consultation, the deadline for consultation comments will remain as is.